MedInCell Stock Jumps 6% Midday After Technical Rebound
MedInCell's stock saw a sharp increase this Monday at midday, climbing 6.13% to 21.48 euros, amid a strong rebound in the Paris market. The Montpellier-based biopharmaceutical company's stock thus recovers some of the losses accumulated in recent months, after a decline of nearly 16% over three months. The CAC 40 is up 0.61% during the session, driven by a de-escalation of geopolitical tensions.
MedInCell's stock has rebounded from the support threshold at 20.24 euros, exactly matching Friday's closing price. This level, tested at the end of last week, appears to have formed a short-term technical floor. However, the stock is still significantly below its 50-day (24.09 euros) and 200-day (23.24 euros) moving averages, indicating that the medium-term downward trend remains intact despite today's surge. The RSI, at 35, is near the oversold zone (below 30), a level that generally signals excessive selling pressure that could favor a corrective rebound. The most significant resistance is at 25.02 euros, about 18% above the current price. Over one year, the stock still maintains a positive performance of over 40%, reflecting the strong revaluation achieved during the past fiscal year.
Following a Dramatic Turnaround in the Paris Market
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
MedInCell's progress occurs in the wake of a dramatic turnaround in the Paris market this Monday. After dropping more than 2% in the morning due to sharp fears over the threat of US strikes against Iran, the CAC 40 abruptly reversed its course following the announcement by Washington of 'very successful' talks with Tehran and the postponement of military operations. The SBF 120 concurrently rose by 0.63% in session. Among comparable health sector stocks, Sanofi remains almost stable (+0.06%) while UCB is up by 0.89%. MedInCell's low beta (0.08) typically indicates a limited correlation with major indices, suggesting that today's movement could also reflect factors specific to the stock, including a technical buyback after several weeks of decline. On the financial calendar, the next major milestone for the company is the publication of its annual results for the fiscal year 2025-2026, scheduled for June 16, 2026.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
